Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) reports financial results for the second quarter and first half of 2020, ending June 30, 2020. The report reflects the impact of the COVID-19 pandemic, which disrupted operations, particularly in the Vaccines business due to limited healthcare visits. The filing also details the completion of the divestment of Horlicks and other Consumer Healthcare nutrition products to Unilever and the ongoing integration of the Pfizer Consumer Healthcare portfolio.
Key Financial Metrics
Quarter 2 2020 Performance
- Turnover: £7.624 billion (down 2% at Actual Exchange Rates (AER), down 3% at Constant Exchange Rates (CER)).
- Total Operating Profit: £2.850 billion (up 92% AER), driven by asset disposals.
- Adjusted Operating Profit: £1.749 billion (down 19% AER, down 21% CER).
- Adjusted Operating Margin: 22.9%.
- Total EPS: 45.5p (up >100% AER).
- Adjusted EPS: 19.2p (down 37% AER, down 38% CER).
- Free Cash Flow: £1.949 billion (up >100% vs Q2 2019).
Half Year 2020 Performance
- Turnover: £16.714 billion (up 8% AER, up 8% CER).
- Total Operating Profit: £4.864 billion (up 67% AER).
- Adjusted Operating Profit: £4.424 billion (up 2% AER, up 2% CER).
- Adjusted Operating Margin: 26.5%.
- Total EPS: 77.0p (up >100% AER).
- Adjusted EPS: 56.9p (down 6% AER, down 6% CER).
- Free Cash Flow: £2.480 billion (up >100% vs H1 2019).
- Net Debt: £23.435 billion at June 30, 2020 (down from £25.215 billion at Dec 31, 2019).
Material Changes vs. Prior Period
- Segment Performance:
- Pharmaceuticals: Q2 turnover down 5% AER due to destocking and lower demand for antibiotics; Respiratory sales up 17% AER driven by Trelegy and Nucala.
- Vaccines: Q2 turnover down 29% AER due to COVID-19 containment measures limiting vaccination visits.
- Consumer Healthcare: Q2 turnover up 25% AER, largely driven by the inclusion of the Pfizer portfolio.
- One-off Items: Total results were significantly boosted by a net profit on the disposal of Horlicks and other Consumer Healthcare brands (£2.304 billion gain) and asset disposals, offset by re-measurement charges on contingent consideration liabilities (£368 million).
- Cost Structure: Adjusted R&D expenditure increased 13% AER in Q2, reflecting significant investment in Oncology and COVID-19 programs.
Guidance, Outlook, and Risks
- 2020 Guidance: GSK maintains its full-year 2020 Adjusted EPS guidance of a decline in the range of -1% to -4% at CER.
- Key Risks:
- COVID-19 Impact: Performance remains dependent on the timing of recovery in vaccination rates, particularly in the US. A three-month delay in recovery could impact Adjusted EPS by up to 5 percentage points.
- Contingent Consideration: Significant volatility in earnings due to re-measurement of liabilities related to ViiV Healthcare (Shionogi) and Novartis Vaccines acquisitions.
- Legal Matters: Ongoing investigations regarding Zantac (ranitidine) and other product liability claims.
- Dividends: The Board declared a second interim dividend of 19 pence per share, maintaining the 2020 annual dividend at 80 pence per share.
Investor Verification Checklist
- Verify the sustainability of the Q2 Total EPS increase, which is heavily influenced by non-recurring asset disposal gains rather than core operating performance.
- Monitor the recovery trajectory of Vaccines sales in the US and Europe as a primary driver for meeting full-year Adjusted EPS guidance.
- Review the reconciliation of Total to Adjusted results to understand the magnitude of contingent consideration re-measurement charges (£368 million in Q2).
- Assess the impact of the Pfizer Consumer Healthcare integration on margins and the timeline for realizing synergy savings.
- Track the status of the Zantac litigation and potential financial exposure beyond current provisions.